- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00098397
FR901228 in Treating Patients With Metastatic Breast Cancer
A Phase II Study Of Single Agent Depsipeptide (FK228) In Breast Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the efficacy and safety of FR901228 (depsipeptide) in patients with metastatic breast cancer.
SECONDARY OBJECTIVES:
I. Determine the clinical activity of this drug, in terms of progression-free survival, in these patients.
OUTLINE: This is a multicenter study.
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 2.4-12.3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed breast cancer
- Metastatic disease
Measurable disease
- At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
The following are not considered measurable disease:
- Bone disease only
- Pleural effusion
- Peritoneal effusion
Must have received prior anthracycline (doxorubicin or epirubicin) and/or taxane (paclitaxel or docetaxel) as adjuvant therapy or for advanced disease
- Therapy with high-dose regimens or bone marrow transplantation is considered 1 prior regimen
- No known brain metastases
Hormone receptor status:
- Not specified
- Male or female
- Performance status - ECOG 0-1
- Performance status - Karnofsky 70-100%
- More than 12 weeks
- Absolute neutrophil count ≥ 1,500/mm^3
- WBC ≥ 3,000/mm^3
- Platelet count ≥ 100,000/mm^3
- Bilirubin normal
- AST or ALT ≤ 2.5 times upper limit of normal
- Creatinine normal
- Creatinine clearance ≥ 60 mL/min
- QTc < 500 msec
- No New York Heart Association class III or IV congestive heart failure
- No myocardial infarction within the past year
- No uncontrolled dysrhythmia
- No poorly controlled angina
- No other significant cardiac disease
- No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No history of allergic reaction attributed to compounds of similar chemical or biologic composition to FR901228
- No active or ongoing infection
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
- No concurrent biologic agents
- No more than 1 prior chemotherapy regimen for metastatic disease
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No prior FR901228 (depsipeptide)
- No other concurrent chemotherapy
- Prior hormonal therapy for metastatic disease or as adjuvant therapy allowed
- More than 4 weeks since prior radiotherapy and recovered
- No concurrent radiotherapy
- More than 2 weeks since prior minor surgery and recovered
- More than 4 weeks since prior major surgery and recovered
- Concurrent bisphosphonates allowed provided therapy was initiated ≥ 3 months ago
- No concurrent agents that cause QTc prolongation
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent drugs known to have histone deacetylase activity (e.g., valproic acid)
- No other concurrent investigational agents
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (romidepsin)
Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Optional correlative studies
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy (complete and partial response) according to RECIST
Time Frame: Up to 14 months
|
Up to 14 months
|
Progression-free survival
Time Frame: From the first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 14 months
|
From the first day of treatment to the first observation of disease progression or death due to any cause, assessed up to 14 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Toxicity as measured by the standard WHO grading system
Time Frame: Up to 14 months after completion of study treatment
|
Up to 14 months after completion of study treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Massimo Cristofanilli, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2012-02641
- N01CM17003 (U.S. NIH Grant/Contract)
- MDA-2003-0895
- CDR0000404163 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Male Breast Cancer
-
Centro Hospitalar Lisboa OcidentalInstituto Nacional de Medicina Legal e Ciências Forenses, Delegação do SulUnknownMale Breast Cancer | Female Breast Cancer
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)WithdrawnHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast CancerUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedMale Breast Cancer | Breast - FemaleUnited States
-
National Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedBreast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
Organon and CoInstitute for Applied Economics and Health Research ApsCompleted
Clinical Trials on romidepsin
-
CelgeneCompletedCarcinoma, Renal Cell | Prostatic NeoplasmsUnited States, United Kingdom
-
CelgeneCompletedCarcinoma, Renal Cell | Neoplasm MetastasisUnited States
-
National Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)CompletedLymphomaUnited States
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative NeoplasmsUnited States
-
National Cancer Institute (NCI)CompletedGastrointestinal Stromal Tumor | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Rhabdomyosarcoma | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal... and other conditions
-
National Cancer Institute (NCI)TerminatedNeoplasms | Mycosis Fungoides | Cutaneous T-Cell LymphomaUnited States
-
University of ChicagoNational Cancer Institute (NCI)WithdrawnOvarian CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell LymphomaUnited States